Clinical Research Directory
Browse clinical research sites, groups, and studies.
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
Sponsor: AstraZeneca
Summary
This is a multi-centre, observational study, with retrospective data collection and prospective active follow-up. The aim is to measure the treatment pattern and real-world outcomes of EGFR-TKI as an adjuvant therapy in patients with early-stage EGFR-mutated NSCLC. The study period ranges from July 1st, 2022 to June 30th, 2031. Approximately 2,000 patients will be enrolled from 15 sites in China.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
2000
Start Date
2026-06-22
Completion Date
2031-06-30
Last Updated
2026-08-13
Healthy Volunteers
No
Conditions
Locations (14)
Research Site
Beijing, China
Research Site
Chengdu, China
Research Site
Fuzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Nanchang, China
Research Site
Shanghai, China
Research Site
Shenyang, China
Research Site
Shijiazhuang, China
Research Site
Tianjin, China
Research Site
Wuhan, China
Research Site
Xi'an, China
Research Site
Xuzhou, China
Research Site
Zhengzhou, China